Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study

Authors: Oscar Arrieta, Rosa M Michel Ortega, Geraldine Villanueva-Rodríguez, Maria G Serna-Thomé, Diana Flores-Estrada, Consuelo Diaz-Romero, Cindy M Rodríguez, Luis Martínez, Karla Sánchez-Lara

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

A frequent manifestation of advanced NSCLC is malnutrition, even though there are many studies which relate it with a poor survival, its relation with toxicity has not yet been consistently reported. The aim of this study was to associate malnutrition and albumin serum levels with the occurrence of chemotherapy-induced toxicity in cisplatin plus paclitaxel chemotherapy-treated NSCLC.

Methods

We prospectively evaluated 100 stage IV NSCLC patients treated with paclitaxel (175 mg/m2) and cisplatin (80 mg/m2). Malnutrition was assessed using SGA prior treatment. Neutrophil Lymphocyte Ratio (NLR) and the Platelet Lymphocyte Ratio (PLR) were used to determine the presence of systemic inflammatory response (SIR) and were related to the development of toxicity. Toxicity was graded according to NCI CTCAE version 3.0 after two chemotherapy cycles.

Results

Median age was 58 ± 10 years, 51% of patients were malnourished, 50% had albumin ≤3.0 mg/mL. NLR ≥ 5 was associated with basal hypoalbuminemia (mean ranks, 55.7 vs. 39 p = 0.006), ECOG = 2 (47.2 vs. 55.4 p = 0.026) and PLR ≥ 150 were significantly related with a basal body mass index ≤20 (56.6 vs. 43.5; p = 0.02) and hypoalbuminemia (58.9 vs. 41.3; p = 0.02). Main toxicities observed after 2 cycles of chemotherapy were alopecia (84%), nausea (49%), neuropathy (46%), anemia (33%), lymphopenia (31%), and leukopenia (30%). Patients malnourished and with hypoalbuminemia developed more chemotherapy-induced toxicity overall when compared with those without malnutrition (31 vs 22; p = 0.02) and normal albumin (mean ranks, 62 vs 43; p = 0.002), respectively. Hypoalbuminemia was associated with anemia (56 vs 47; p = 0.05), fatigue (58 vs 46; p = 0.01), and appetite loss (57.1 vs 46.7; p = 0.004) compared with normal albumin. PLR ≥ 150 was related with the development of toxicity grade III/IV (59.27 vs. 47.03 p = 0.008) and anemia (37.9 vs 53.8 p = 0.004).

Conclusion

SIR parameters were associated with malnutrition, weight loss and hypoalbuminemia. Chemotherapy-induced toxicity in NSCLC patients treated with paclitaxel and cisplatin was associated with malnutrition and hypoalbuminemia. Early nutritional assessment and support might confer beneficial effects.
Literature
1.
go back to reference Danaei G, Hoorn Vander S, Lopez AD, Murray CJ, Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005, 366 (9499): 1784-93. 10.1016/S0140-6736(05)67725-2.CrossRefPubMed Danaei G, Hoorn Vander S, Lopez AD, Murray CJ, Ezzati M: Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005, 366 (9499): 1784-93. 10.1016/S0140-6736(05)67725-2.CrossRefPubMed
2.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA: a cancer journal for clinicians. 2008, 58 (2): 71-96. 10.3322/CA.2007.0010.
3.
go back to reference Lazcano Ponce EC, Tovar Guzman V, Meneses Gonzalez F, Rascon Pacheco RA, Hernandez Avila M: Trends of lung cancer mortality in Mexico. Archives of medical research. 1997, 28 (4): 565-70.PubMed Lazcano Ponce EC, Tovar Guzman V, Meneses Gonzalez F, Rascon Pacheco RA, Hernandez Avila M: Trends of lung cancer mortality in Mexico. Archives of medical research. 1997, 28 (4): 565-70.PubMed
4.
go back to reference Ginsberg RJ, Vokes EE, Raben A: Cancer of the lung, section 2: non-small cell lung cancer. Cancer: Principles & Practice. Edited by: De Vita VT, Hellman S, Rosenberg SA. 1997, Lippincott Williams & Wilkins, 858-8 Ginsberg RJ, Vokes EE, Raben A: Cancer of the lung, section 2: non-small cell lung cancer. Cancer: Principles & Practice. Edited by: De Vita VT, Hellman S, Rosenberg SA. 1997, Lippincott Williams & Wilkins, 858-8
5.
go back to reference Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999, 17 (10): 3188-94.PubMed Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL: Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol. 1999, 17 (10): 3188-94.PubMed
6.
go back to reference Harper P: Current clinical practices for ovarian cancers. Seminars in oncology. 2002, 29 (3 Suppl 8): 3-6. 10.1053/sonc.2002.33525.CrossRefPubMed Harper P: Current clinical practices for ovarian cancers. Seminars in oncology. 2002, 29 (3 Suppl 8): 3-6. 10.1053/sonc.2002.33525.CrossRefPubMed
7.
go back to reference Seidman AD: Monotherapy options in the management of metastatic breast cancer. Seminars in oncology. 2003, 30 (2 Suppl 3): 6-10.CrossRefPubMed Seidman AD: Monotherapy options in the management of metastatic breast cancer. Seminars in oncology. 2003, 30 (2 Suppl 3): 6-10.CrossRefPubMed
8.
go back to reference Rinaldi M, Cauchi C, Gridelli C: First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol. 2006, 17 (Suppl 5): v64-7. 10.1093/annonc/mdj953.CrossRefPubMed Rinaldi M, Cauchi C, Gridelli C: First line chemotherapy in advanced or metastatic NSCLC. Ann Oncol. 2006, 17 (Suppl 5): v64-7. 10.1093/annonc/mdj953.CrossRefPubMed
9.
go back to reference Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002, 20 (20): 4191-8. 10.1200/JCO.2002.03.054.CrossRefPubMed Vokes EE, Herndon JE, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol. 2002, 20 (20): 4191-8. 10.1200/JCO.2002.03.054.CrossRefPubMed
10.
go back to reference Rowinsky EK, Donehower RC: Paclitaxel (taxol). The New England journal of medicine. 1995, 332 (15): 1004-14. 10.1056/NEJM199504133321507.CrossRefPubMed Rowinsky EK, Donehower RC: Paclitaxel (taxol). The New England journal of medicine. 1995, 332 (15): 1004-14. 10.1056/NEJM199504133321507.CrossRefPubMed
11.
go back to reference Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998, 55 (1): 5-30. 10.2165/00003495-199855010-00002.CrossRefPubMed Eisenhauer EA, Vermorken JB: The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs. 1998, 55 (1): 5-30. 10.2165/00003495-199855010-00002.CrossRefPubMed
12.
go back to reference Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998, 16 (5): 1811-9.PubMed Venook AP, Egorin MJ, Rosner GL, Brown TD, Jahan TM, Batist G, Hohl R, Budman D, Ratain MJ, Kearns CM, Schilsky RL: Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264. J Clin Oncol. 1998, 16 (5): 1811-9.PubMed
13.
go back to reference Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N: Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. Japanese journal of clinical oncology. 2003, 33 (12): 626-30. 10.1093/jjco/hyg116.CrossRefPubMed Watanabe H, Yamamoto N, Tamura T, Shimoyama T, Hotta K, Inoue A, Sawada M, Akiyama Y, Kusaba H, Nokihara H, Sekine I, Kunitoh H, Ohe Y, Kodama T, Saijo N: Study of paclitaxel and dose escalation of cisplatin in patients with advanced non-small cell lung cancer. Japanese journal of clinical oncology. 2003, 33 (12): 626-30. 10.1093/jjco/hyg116.CrossRefPubMed
14.
go back to reference Timmer-Bonte JN, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, Huitema AD, Tjan-Heijnen VC: Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2008, 60 (2): 222-30.CrossRef Timmer-Bonte JN, Punt CJ, vd Heijden HF, van Die CE, Bussink J, Beijnen JH, Huitema AD, Tjan-Heijnen VC: Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands). 2008, 60 (2): 222-30.CrossRef
15.
go back to reference Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR: Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Annals of neurology. 1994, 35 (3): 304-11. 10.1002/ana.410350310.CrossRefPubMed Chaudhry V, Rowinsky EK, Sartorius SE, Donehower RC, Cornblath DR: Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Annals of neurology. 1994, 35 (3): 304-11. 10.1002/ana.410350310.CrossRefPubMed
16.
go back to reference Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993, 11 (10): 2010-20.PubMed Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 1993, 11 (10): 2010-20.PubMed
17.
18.
go back to reference McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009, 12 (3): 223-6. 10.1097/MCO.0b013e32832a7902.CrossRefPubMed McMillan DC: Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009, 12 (3): 223-6. 10.1097/MCO.0b013e32832a7902.CrossRefPubMed
19.
go back to reference Vassallo JABE: Actualización Ponderada de los Factores de Riesgo del Cáncer. 2003, Montevideo: Comisión Honoraria de Lucha contra el Cáncer Vassallo JABE: Actualización Ponderada de los Factores de Riesgo del Cáncer. 2003, Montevideo: Comisión Honoraria de Lucha contra el Cáncer
20.
go back to reference Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F: Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006, 42 (1): 31-41. 10.1016/j.ejca.2005.07.026.CrossRefPubMed Muscaritoli M, Bossola M, Aversa Z, Bellantone R, Rossi Fanelli F: Prevention and treatment of cancer cachexia: new insights into an old problem. Eur J Cancer. 2006, 42 (1): 31-41. 10.1016/j.ejca.2005.07.026.CrossRefPubMed
21.
go back to reference Ottery FD: Cancer cachexia: prevention, early diagnosis, and management. Cancer practice. 1994, 2 (2): 123-31.PubMed Ottery FD: Cancer cachexia: prevention, early diagnosis, and management. Cancer practice. 1994, 2 (2): 123-31.PubMed
22.
go back to reference Lochs H, Dervenis C: Malnutrition--the ignored risk factor. Digestive diseases (Basel, Switzerland). 2003, 21 (3): 196-7.CrossRef Lochs H, Dervenis C: Malnutrition--the ignored risk factor. Digestive diseases (Basel, Switzerland). 2003, 21 (3): 196-7.CrossRef
23.
go back to reference Bauer J, Capra S, Ferguson M: Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. European journal of clinical nutrition. 2002, 56 (8): 779-85. 10.1038/sj.ejcn.1601412.CrossRefPubMed Bauer J, Capra S, Ferguson M: Use of the scored Patient-Generated Subjective Global Assessment (PG-SGA) as a nutrition assessment tool in patients with cancer. European journal of clinical nutrition. 2002, 56 (8): 779-85. 10.1038/sj.ejcn.1601412.CrossRefPubMed
24.
go back to reference Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN: Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. Jpen. 1984, 8 (2): 153-9.CrossRef Detsky AS, Baker JP, Mendelson RA, Wolman SL, Wesson DE, Jeejeebhoy KN: Evaluating the accuracy of nutritional assessment techniques applied to hospitalized patients: methodology and comparisons. Jpen. 1984, 8 (2): 153-9.CrossRef
25.
go back to reference Kuzuya M, Kanda S, Koike T, Suzuki Y, Satake S, Iguchi A: Evaluation of Mini-Nutritional Assessment for Japanese frail elderly. Nutrition (Burbank, Los Angeles County, Calif). 2005, 21 (4): 498-503.CrossRef Kuzuya M, Kanda S, Koike T, Suzuki Y, Satake S, Iguchi A: Evaluation of Mini-Nutritional Assessment for Japanese frail elderly. Nutrition (Burbank, Los Angeles County, Calif). 2005, 21 (4): 498-503.CrossRef
26.
go back to reference Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A: Malnutrition among gynaecological cancer patients. European journal of clinical nutrition. 2007, 61 (5): 642-6.PubMed Laky B, Janda M, Bauer J, Vavra C, Cleghorn G, Obermair A: Malnutrition among gynaecological cancer patients. European journal of clinical nutrition. 2007, 61 (5): 642-6.PubMed
27.
go back to reference Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M: The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007, 73 (3-4): 215-20. 10.1159/000127412. Epub 2008 Apr 17CrossRefPubMed Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M: The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007, 73 (3-4): 215-20. 10.1159/000127412. Epub 2008 Apr 17CrossRefPubMed
28.
go back to reference Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E: Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009, 137 (2): 425-8. 10.1016/j.jtcvs.2008.05.046. Epub 2008 Aug 29CrossRefPubMed Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E: Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009, 137 (2): 425-8. 10.1016/j.jtcvs.2008.05.046. Epub 2008 Aug 29CrossRefPubMed
29.
go back to reference Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005, 91 (3): 181-4. 10.1002/jso.20329.CrossRefPubMed Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ: Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005, 91 (3): 181-4. 10.1002/jso.20329.CrossRefPubMed
30.
go back to reference Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009, 197 (4): 466-72. 10.1016/j.amjsurg.2007.12.057. Epub 2008 Jul 17CrossRefPubMed Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, Ghaneh P: Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009, 197 (4): 466-72. 10.1016/j.amjsurg.2007.12.057. Epub 2008 Jul 17CrossRefPubMed
31.
go back to reference Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L: Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003, 11 (10): 652-9. 10.1007/s00520-003-0486-0.CrossRefPubMed Sarhill N, Mahmoud F, Walsh D, Nelson KA, Komurcu S, Davis M, LeGrand S, Abdullah O, Rybicki L: Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer. 2003, 11 (10): 652-9. 10.1007/s00520-003-0486-0.CrossRefPubMed
32.
go back to reference Busch E, Verazin G, Antkowiak JG, Driscoll D, Takita H: Pulmonary complications in patients undergoing thoracotomy for lung carcinoma. Chest. 1994, 105 (3): 760-6. 10.1378/chest.105.3.760.CrossRefPubMed Busch E, Verazin G, Antkowiak JG, Driscoll D, Takita H: Pulmonary complications in patients undergoing thoracotomy for lung carcinoma. Chest. 1994, 105 (3): 760-6. 10.1378/chest.105.3.760.CrossRefPubMed
33.
go back to reference Bashir Y, Graham TR, Torrance A, Gibson GJ, Corris PA: Nutritional state of patients with lung cancer undergoing thoracotomy. Thorax. 1990, 45 (3): 183-6. 10.1136/thx.45.3.183.CrossRefPubMedPubMedCentral Bashir Y, Graham TR, Torrance A, Gibson GJ, Corris PA: Nutritional state of patients with lung cancer undergoing thoracotomy. Thorax. 1990, 45 (3): 183-6. 10.1136/thx.45.3.183.CrossRefPubMedPubMedCentral
34.
go back to reference McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008, 67 (3): 257-62. 10.1017/S0029665108007131. Epub 2008 May 1CrossRefPubMed McMillan DC: An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008, 67 (3): 257-62. 10.1017/S0029665108007131. Epub 2008 May 1CrossRefPubMed
35.
go back to reference Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pellicciotta M, Ceribelli A, De Marco S, Facciolo F, Cognetti F: The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res. 2004, 23 (1): 25-32.PubMed Fabi A, Barduagni M, Ferraresi V, Cortesi E, Gamucci T, De Marinis F, Saltarelli R, Gabriele A, Pellicciotta M, Ceribelli A, De Marco S, Facciolo F, Cognetti F: The combination of carboplatin and weekly paclitaxel: a safe and active regimen in advanced non small-cell lung cancer patients. A phase I-II study. J Exp Clin Cancer Res. 2004, 23 (1): 25-32.PubMed
36.
go back to reference Paal K, Shkarupin A: Paclitaxel binding to the fatty acid-induced conformation of human serum albumin--automated docking studies. Bioorganic & medicinal chemistry. 2007, 15 (24): 7568-75. 10.1016/j.bmc.2007.09.006.CrossRef Paal K, Shkarupin A: Paclitaxel binding to the fatty acid-induced conformation of human serum albumin--automated docking studies. Bioorganic & medicinal chemistry. 2007, 15 (24): 7568-75. 10.1016/j.bmc.2007.09.006.CrossRef
37.
go back to reference Kratz F, Ehling G, Kauffmann HM, Unger C: Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Human & experimental toxicology. 2007, 26 (1): 19-35. 10.1177/0960327107073825.CrossRef Kratz F, Ehling G, Kauffmann HM, Unger C: Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Human & experimental toxicology. 2007, 26 (1): 19-35. 10.1177/0960327107073825.CrossRef
38.
go back to reference D'Angio RG: Is there a role for albumin administration in nutrition support?. The Annals of pharmacotherapy. 1994, 28 (4): 478-82.PubMed D'Angio RG: Is there a role for albumin administration in nutrition support?. The Annals of pharmacotherapy. 1994, 28 (4): 478-82.PubMed
39.
go back to reference Guthrie RD, Hines C: Use of intravenous albumin in the critically ill patient. The American journal of gastroenterology. 1991, 86 (3): 255-63.PubMed Guthrie RD, Hines C: Use of intravenous albumin in the critically ill patient. The American journal of gastroenterology. 1991, 86 (3): 255-63.PubMed
40.
go back to reference Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003, 89 (6): 1028-30. 10.1038/sj.bjc.6601242.CrossRefPubMedPubMedCentral Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003, 89 (6): 1028-30. 10.1038/sj.bjc.6601242.CrossRefPubMedPubMedCentral
41.
go back to reference Holroyde CP, Reichard GA: General metabolic abnormalities in cancer patients: anorexia and cachexia. The Surgical clinics of North America. 1986, 66 (5): 947-56.PubMed Holroyde CP, Reichard GA: General metabolic abnormalities in cancer patients: anorexia and cachexia. The Surgical clinics of North America. 1986, 66 (5): 947-56.PubMed
42.
go back to reference Wilson DO, Rogers RM, Hoffman RM: Nutrition and chronic lung disease. The American review of respiratory disease. 1985, 132 (6): 1347-65.PubMed Wilson DO, Rogers RM, Hoffman RM: Nutrition and chronic lung disease. The American review of respiratory disease. 1985, 132 (6): 1347-65.PubMed
43.
go back to reference Morss Dy S: Enteral and Parenteral Nutrition in Terminally Ill Cancer Patients: A Review of the Literature. Am J Hosp Palliat Care. 2006, 23: 369-77. 10.1177/1049909106292167.CrossRef Morss Dy S: Enteral and Parenteral Nutrition in Terminally Ill Cancer Patients: A Review of the Literature. Am J Hosp Palliat Care. 2006, 23: 369-77. 10.1177/1049909106292167.CrossRef
44.
go back to reference Casado-Cobo SCR: Dietary interventions in Cancer. Rev Oncol. 2004, 6: 496-500. Casado-Cobo SCR: Dietary interventions in Cancer. Rev Oncol. 2004, 6: 496-500.
45.
go back to reference Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Comparison of aninflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004, 90 (9): 1704-6.PubMedPubMedCentral Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ: Comparison of aninflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004, 90 (9): 1704-6.PubMedPubMedCentral
46.
go back to reference Gabay C, Kushner I: Acute-phase proteins and other systemic responses to in6lammation. N Engl J Med. 1999, 340: 448-454. 10.1056/NEJM199902113400607.CrossRefPubMed Gabay C, Kushner I: Acute-phase proteins and other systemic responses to in6lammation. N Engl J Med. 1999, 340: 448-454. 10.1056/NEJM199902113400607.CrossRefPubMed
47.
go back to reference Nakahara Y, Mochiduki Y, Miyamoto Y, Nakahara Y, Katsura Y: Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer. 2005, 104 (6): 1271-80. 10.1002/cncr.21290.CrossRefPubMed Nakahara Y, Mochiduki Y, Miyamoto Y, Nakahara Y, Katsura Y: Prognostic significance of the lymphocyte-to-neutrophil ratio in percutaneous fine-needle aspiration biopsy specimens of advanced nonsmall cell lung carcinoma. Cancer. 2005, 104 (6): 1271-80. 10.1002/cncr.21290.CrossRefPubMed
48.
go back to reference Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Adizzoia A, Gardani GS: Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers. 2004, 19 (2): 135-40.PubMed Lissoni P, Brivio F, Fumagalli L, Messina G, Ghezzi V, Frontini L, Giani L, Vaghi M, Adizzoia A, Gardani GS: Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers. 2004, 19 (2): 135-40.PubMed
49.
go back to reference Sung JBG, Joshi M, Bochicchio K, Costas A, Tracy K, Scalea TM: Admission serum albumin is predicitve of outcome in critically ill trauma patients. Am Surg. 2004, 70: 1099-102.PubMed Sung JBG, Joshi M, Bochicchio K, Costas A, Tracy K, Scalea TM: Admission serum albumin is predicitve of outcome in critically ill trauma patients. Am Surg. 2004, 70: 1099-102.PubMed
50.
go back to reference Kuzuya MIS, Enoki H, Okada K, Iguchi A: Is serum albumin a good marker for malnutrition in the physically impaired elderly?. Clin Nutr. 2007, 26: 84-90. 10.1016/j.clnu.2006.07.009.CrossRefPubMed Kuzuya MIS, Enoki H, Okada K, Iguchi A: Is serum albumin a good marker for malnutrition in the physically impaired elderly?. Clin Nutr. 2007, 26: 84-90. 10.1016/j.clnu.2006.07.009.CrossRefPubMed
51.
go back to reference Win TRA, Wells F, Laroche C: The incidence and impact of low body mass index on patients with operable lung cancer. Clin Nutr. 2007, 26: 440-43. 10.1016/j.clnu.2007.01.009.CrossRefPubMed Win TRA, Wells F, Laroche C: The incidence and impact of low body mass index on patients with operable lung cancer. Clin Nutr. 2007, 26: 440-43. 10.1016/j.clnu.2007.01.009.CrossRefPubMed
52.
go back to reference Numeroso F, Barilli AL, Delsignore R: Prevalence and significance of hypoalbuminemia in an internal medicine department. European journal of internal medicine. 2008, 19 (8): 587-91. 10.1016/j.ejim.2007.04.029.CrossRefPubMed Numeroso F, Barilli AL, Delsignore R: Prevalence and significance of hypoalbuminemia in an internal medicine department. European journal of internal medicine. 2008, 19 (8): 587-91. 10.1016/j.ejim.2007.04.029.CrossRefPubMed
53.
go back to reference Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S: A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987, 5 (1): 113-24.PubMed Evans WK, Nixon DW, Daly JM, Ellenberg SS, Gardner L, Wolfe E, Shepherd FA, Feld R, Gralla R, Fine S: A randomized study of oral nutritional support versus ad lib nutritional intake during chemotherapy for advanced colorectal and non-small-cell lung cancer. J Clin Oncol. 1987, 5 (1): 113-24.PubMed
Metadata
Title
Association of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study
Authors
Oscar Arrieta
Rosa M Michel Ortega
Geraldine Villanueva-Rodríguez
Maria G Serna-Thomé
Diana Flores-Estrada
Consuelo Diaz-Romero
Cindy M Rodríguez
Luis Martínez
Karla Sánchez-Lara
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-50

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine